CRH (CRH) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
13 Mar, 2026Executive summary
Delivered record 2025 financial results: revenues up 5% to $37.4B, net income up 8% to $3.8B, Adjusted EBITDA up 11% to $7.7B, and Diluted EPS up 10% to $5.51.
Achieved Total Shareholder Return of 36.8% for 2025, with share price rising from $92.52 to $124.80.
Invested $4.1B in 38 acquisitions, including $2.1B for Eco Material Technologies, and $1.7B in growth capex.
Continued share buybacks ($1.2B) and increased dividend by 6% to $1.48 per share.
Announced intention to delist from the LSE and cancel legacy Preference Shares, subject to shareholder approval.
Voting matters and shareholder proposals
12 proposals at the 2026 AGM: re-election of 12 directors, advisory vote on executive compensation, auditor appointment and compensation, renewal of share issuance and buyback authorities, cancellation of Preference Shares, and amendments to Articles.
Special business includes cancellation of 5% and 7% Preference Shares via court-approved schemes, with cash consideration at a significant premium to nominal value.
Proposal to amend Articles to remove director qualification shareholding requirement.
Board of directors and corporate governance
Board comprises 12 directors with diverse backgrounds and skills; all standing for re-election.
Board evaluation process includes external facilitation; annual review of director performance and independence.
Five standing committees: Audit, Compensation, Nomination & Corporate Governance, Acquisitions/Divestments & Finance, and Safety, Environment & Social Responsibility.
Chair and CEO roles are separated; robust succession planning in place.
Latest events from CRH
- Delisting and preference share cancellations aim to simplify capital structure and cut costs.CRH
Proxy Filing13 Mar 2026 - Record 2025 financials, double-digit EBITDA growth, and strong 2026 outlook on infrastructure demand.CRH
Q4 202519 Feb 2026 - Q2 net income up 8%, EBITDA up 12%, margins expanded, and FY24 guidance raised.CRH
H1 20242 Feb 2026 - Q3 saw strong sales, margin gains, and M&A, with a positive outlook reaffirmed.CRH
Q3 2024 TU16 Jan 2026 - Double-digit profit growth and margin expansion achieved, with strong 2025 outlook.CRH
H2 20247 Jan 2026 - Record Q3, raised FY25 EBITDA guidance, and strong outlook driven by demand and acquisitions.CRH
Q3 2025 TU21 Dec 2025 - Record financials, new equity plan, governance updates, and strong ESG progress headline the proxy.CRH
Proxy Filing2 Dec 2025 - Record results, NYSE transition, new CEO, and 12 key AGM proposals mark a transformative year.CRH
Proxy Filing2 Dec 2025 - Definitive additional proxy materials filed for upcoming shareholder meeting.CRH
Proxy Filing2 Dec 2025